Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.50 |
| ▸ | THRA | P10827 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 3/20 | 0.44 |
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | RXRA | P19793 | 2/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGAV | P06756 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.36 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.36 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9319512 | 0.85 | TTR (0.46) | TTRTHRATHRBPPARGRXRA | |
| SCHEMBL9319515 | 0.85 | TTR (0.46) | TTRTHRATHRBPPARGRXRA | |
| SCHEMBL30502430 | 0.82 | TPMT (0.40) | TTRTHRATHRBPPARGRXRA | |
| SCHEMBL19678481 | 0.82 | TPMT (0.40) | TTRTHRATHRBPPARGRXRA | |
| SCHEMBL27185421 | 0.81 | THRA (0.43) | TTRTHRATHRBPPARGRXRA | |
| SCHEMBL27185701 | 0.81 | THRA (0.41) | TTRTHRATHRBPPARGRXRA | |
| SCHEMBL2049716 | 0.77 | TTR (0.64) | TTRERN1MEN1KMT2AALB | |
| SCHEMBL17378819 | 0.76 | THRA (0.37) | TTRTHRATHRBPPARGRXRA | |
| SCHEMBL8462416 | 0.76 | AKR1B1 (0.33) | TTRTHRATHRBPPARGRXRA | |
| SCHEMBL8464249 | 0.76 | AKR1B1 (0.33) | TTRTHRATHRBPPARGRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102746240-B | anti-infective pyrimidines and uses thereof | 艾伯维巴哈马有限公司 | 2017-10-03 | — | — | CN | disclosed |
| EP-2639226-B1 | Anti-infective pyrimidines and uses thereof | ABBVIE BAHAMAS LTD (BS) | 2016-08-31 | — | — | EP | disclosed |
| CN-105693626-A | Uracil or thymine derivatives for the treatment of hepatitis C | 艾伯维巴哈马有限公司 | 2016-06-22 | — | — | CN | disclosed |
| CN-101918369-B | Uracil or thymine derivatives for the treatment of hepatitis C | ABBVIE INC. (BS) | 2016-02-24 | — | — | CN | disclosed |
| CN-102746239-B | Uracil or thymine derivatives for the treatment of hepatitis C | ABBVIE INC. (BS) | 2016-02-10 | — | — | CN | disclosed |
| CN-105294569-A | Uracil or thymine derivatives for the treatment of hepatitis C | ABBVIE INC | 2016-02-03 | — | — | CN | disclosed |
| US-9139536-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9095590-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2015-08-04 | — | — | US | disclosed |
| CN-104628654-A | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | ABBVIE BAHAMAS LTD | 2015-05-20 | — | — | CN | disclosed |
| CN-104628655-A | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | ABBVIE BAHAMAS LTD | 2015-05-20 | — | — | CN | disclosed |
| CN-101842360-A | Anti-infective pyrimidines and uses thereof | ABBOTT LAB | 2010-09-22 | — | — | CN | disclosed |
| EP-2222646-A1 | URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C | Abbott Laboratories (US) | 2010-09-01 | — | — | EP | disclosed |
| CN-101801935-A | Uracil or thymine derivatives for the treatment of hepatitis C | ABBOTT LAB | 2010-08-11 | — | — | CN | disclosed |
| EP-2203431-A1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | Abbott Laboratories (US) | 2010-07-07 | — | — | EP | disclosed |
| EP-2203430-A1 | N-PHENYL-DIOXO-HYDROPYRIMIDINES USEFUL AS HEPATITIS C VIRUS (HCV) INHIBITORS | Abbott Laboratories (US) | 2010-07-07 | — | — | EP | disclosed |
| US-20090186912-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090176784-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | US | disclosed |
| WO-2009039135-A1 | N-PHENYL-DIOXO-HYDROPYRIMIDINES USEFUL AS HEPATITIS C VIRUS (HCV) INHIBITORS | ABBOTT LABORATORIES (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009039134-A1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009039127-A1 | URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C | ABBOTT LABORATORIES (US) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176784-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | MPO, SERPINB1, ELANE | TTR 2021/4885THRA 4220/4885THRB 4470/4885 |
| US-20090186912-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | MPO, SERPINB1, ELANE | TTR 2021/4885THRA 4220/4885THRB 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.